Audentes Therapeutics Appoints Scott W. Morrison to Board of Directors
SAN FRANCISCO, CA– January 5, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the appointment of Scott Morrison to its board of directors. Mr. Morrison will serve as chairman of the Audentes Therapeutics audit committee.
“We are excited to have Scott join the Audentes team,” stated Matthew Patterson, President and Chief Executive Officer. “Scott brings decades of strategic and financial experience in the life sciences industry, and we look forward to the contributions he will make as we work to bring innovative products to patients suffering from devastating rare diseases.”
Mr. Morrison commented, “With its strong leadership team, compelling pipeline and focus on internal manufacturing capabilities, Audentes is well positioned in the emerging field of gene therapy. I look forward to working closely with the board and management team during this stage in the company’s development.”
Mr. Morrison was a Partner with Ernst & Young LLP from 1996 to December 2015, and served as its U.S. Life Sciences Leader from 2002 to December 2015. Mr. Morrison has held roles on the boards of directors of numerous life sciences industry organizations. Since 1999, he has served on the board of directors of the Biotechnology Institute, a nonprofit organization, where he has also served on the audit committee since 2002. Mr. Morrison has previously served on the boards of directors of the Life Sciences Foundation, the Bay Area Biosciences Association and the Emerging Companies Section of the Biotechnology Industry Organization. Mr. Morrison received a B.S. in Accounting and Finance from the University of California-Berkeley.
About Audentes Therapeutics, Inc.
Audentes Therapeutics is a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. We have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome Type 1, AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT) and AT982 for the treatment of Pompe disease. Our team consists of focused, experienced and passionate individuals committed to forging strong, global relationships with the patient, research and medical communities.